Chimerix, Inc. (NASDAQ:CMRX) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Monday.
Separately, Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Wednesday, August 9th.
Chimerix (NASDAQ:CMRX) opened at 5.02 on Monday. Chimerix has a one year low of $3.66 and a one year high of $6.64. The stock’s 50 day moving average is $4.72 and its 200 day moving average is $5.27. The firm’s market cap is $236.17 million.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.05. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. On average, equities research analysts expect that Chimerix will post ($1.63) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Chimerix, Inc. (CMRX) Stock Rating Lowered by ValuEngine” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.chaffeybreeze.com/2017/09/20/chimerix-inc-cmrx-stock-rating-lowered-by-valuengine.html.
A number of institutional investors have recently added to or reduced their stakes in the business. Teachers Advisors LLC raised its stake in Chimerix by 0.3% during the fourth quarter. Teachers Advisors LLC now owns 69,888 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 204 shares in the last quarter. Bank of Montreal Can raised its stake in Chimerix by 3.8% during the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 1,448 shares in the last quarter. American International Group Inc. raised its stake in Chimerix by 7.1% during the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 1,733 shares in the last quarter. Nationwide Fund Advisors raised its stake in Chimerix by 5.9% during the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 1,977 shares in the last quarter. Finally, Alps Advisors Inc. raised its stake in Chimerix by 5.5% during the second quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 2,178 shares in the last quarter. Hedge funds and other institutional investors own 67.53% of the company’s stock.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.